Virbac (CHIX:VIRPP) Total Operating Expense: €745 Mil (TTM As of Dec. 2025)


CHIX:VIRPP Virbac SA CHIX:VIRPP
31 GF Score
Price €334.00
GF Value €373.65
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Virbac Total Operating Expense?

Virbac CHIX:VIRPP 31 Total Operating Expense is €745 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 31/100 and a GF Value™ of €373.65 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Virbac's Total Operating Expense for the six months ended in Dec. 2025 was €381 Mil. Virbac's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €745 Mil.

Virbac Total Operating Expense Related Terms

Virbac Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Virbac's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Total Operating Expense Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 534.11 606.49 623.90 709.30 745.03

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 330.49 331.80 377.50 364.12 380.91
CHIX:VIRPP
31GF Score
Virbac SA CHIX:VIRPP
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €745 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €745 Mil mean?
Virbac (CHIX:VIRPP) has a Total Operating Expense of €745 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Virbac and its competitors.
Is Virbac's Total Operating Expense too high?
Virbac's current Total Operating Expense is €745 Mil. Overall, Virbac has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Total Operating Expense compare to LLY and JNJ?
Virbac's Total Operating Expense of €745 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Virbac and its competitors. Virbac's current Total Operating Expense is €745 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (CHIX:VIRPP) is currently considered Modestly Undervalued. The stock's GF Value™ is €373.65, compared to a current price of €334.00 — trading 10.6% below its estimated fair value. The current Total Operating Expense is €745 Mil. Virbac's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Total Operating Expense is €745 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €334.00 is trading 10.6% below its estimated GF Value™ of €373.65. GuruFocus considers Virbac to be Modestly Undervalued.

Key valuation signals for CHIX:VIRPP:

  • Total Operating Expense: €745 Mil
  • GF Value™: €373.65 vs. price of €334.00 (10.6% below fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
31GF Score

Get the complete analysis for CHIX:VIRPP

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€334.00
Price
€373.65
GF Value